Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Restructures Research Segment, Hopes to Save $3.5M Annually

NEW YORK, July 15 (GenomeWeb News) - Serologicals is cutting costs in its research segment by $3 million to $3.5 million a year by restructuring certain functions, the Atlanta, Ga.-based company said yesterday.


The company will integrate several functions of its Upstate and Chemicon units through the remainder of the year, including business segment management, R&D/business development, marketing, technical support, scientific sourcing, intellectual property/licensing, and finance and accounting.


Serologicals said it expects to incur between $2 million and $3 million in one-time costs related to severance payments, retention payments, and relocation costs that it will record in the third quarter.


Details about job cuts were not provided, and calls to Serologicals were not returned by deadline.


Serologicals, which has more than 1,000 employees worldwide, operates three companies: Chemicon International, based in Temecula, Calif.; Upstate Group, based in Charlottesville, Va.; and Celliance, based in Atlanta.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.